5. Castaigne, S. et al. Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo
acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study. Lancet Lond. Engl. 379,
1508–1516 (2012).
6. Burnett, A. K. et al. Identification of patients with acute myeloblastic leukemia who benefit from
the addition of gemtuzumab ozogamicin: results of the MRC AML15 trial. J. Clin. Oncol. Off. J. Am. Soc.
Clin. Oncol. 29, 369–377 (2011).
7. Burnett, A. K. et al. Addition of gemtuzumab ozogamicin to induction chemotherapy improves
survival in older patients with acute myeloid leukemia. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 30,
3924–3931 (2012).
8. Hills, R. K. et al. Addition of gemtuzumab ozogamicin to induction chemotherapy in adult
patients with acute myeloid leukaemia: a meta-analysis of individual patient data from randomised
controlled trials. Lancet Oncol. 15, 986–996 (2014).
